TY  - JOUR
T1  - IMpact of availability of anti–vascular endothelial growth factor therapy on visual impairment and blindness due to neovascular age-related macular degeneration
AU  - Campbell JP, Bressler SB, Bressler NM
Y1  - 2012/06/01
N1  - 10.1001/archophthalmol.2011.2480
JO  - Archives of Ophthalmology
SP  - 794
EP  - 795
VL  - 130
IS  - 6
N2  - 
Anti–vascular endothelial growth factor (VEGF) therapy has revolutionized the treatment of neovascular age-related macular degeneration (AMD).1- 2 Recent theoretical modeling suggests that monthly anti-VEGF therapy may dramatically decrease the incidence of blindness due to AMD in this country.3 We describe 2 cohorts of patients with incident neovascular AMD in the last decade, selected to have 1 cohort before and 1 after the advent of anti-VEGF therapy to explore whether there are data to support the theoretical model in a clinical practice setting.

SN  - 0003-9950
M3  - doi: 10.1001/archophthalmol.2011.2480
UR  - http://dx.doi.org/10.1001/archophthalmol.2011.2480
ER  -